Post hoc analysis shows a clear correlation between high expression of PDL1 and efficacy of cemiplimab
At WCLC 2020, Dr Saadettin Kilickap reported the results of a post hoc analysis of the phase III EMPOWER-Lung 1 trial evaluating cemiplimab vs platinum-doublet chemotherapy as a frontline treatment in 437 patients with advanced NSCLC with a PD-L1 level ≥ 50%.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in